Lisata Therapeutics Inc
NASDAQ:LSTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lisata Therapeutics Inc
NASDAQ:LSTA
|
US |
|
Guilin Layn Natural Ingredients Corp
SZSE:002166
|
CN |
|
City Developments Ltd
SGX:C09
|
SG |
|
Future Link Network Co Ltd
TSE:9241
|
JP |
|
L
|
LB Aluminium Bhd
KLSE:LBALUM
|
MY |
|
Tsentr Mezhdunarodnoy Torgovli PAO
MOEX:WTCM
|
RU |
|
Deutsche Rohstoff AG
XETRA:DR0
|
DE |
|
C
|
Clubhouse Media Group Inc
OTC:CMGR
|
US |
|
B
|
Bank Albilad Sjsc
SAU:1140
|
SA |
|
C
|
Cts Eventim AG & Co KgaA
OTC:CEVMY
|
DE |
|
A
|
Ashirwad Steels And Industries Ltd
BSE:526847
|
IN |
|
Aditya Birla Fashion and Retail Ltd
NSE:ABFRL
|
IN |
Lisata Therapeutics Inc
Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.
Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
